PTCT News & Events

Unaudited 2025 financial results: Total unaudited product and royalty revenue for full-year 2025 was approximately $823.4M. Total unaudited product revenue for full-year 2025 was approximately $587.8M. Sephience unaudited total net revenue for 2025 was approximately $112.1M. DMD franchise unaudited revenue for full-year 2025 was approximately $381.8M, including unaudited product revenue for Translarna of approximately $235.5M and for Emflaza of approximately $146.3M. PTC expects to report approximately $235.7M of full-year 2025 royalty revenue associated with Evr.

For the full year 2026, PTC anticipates: Total product revenue of $700M-$800M, excluding Evrysdi royalty revenue and collaboration revenue; GAAP R&D and SG&A expense of $775M-$815M; Non-GAAP R&D and SG&A expense of $680M-$720M, excluding estimated non-cash, stock-based compensation expense of $95M.